Clinical characteristics of 128 patients with TAM
| . | All patients, N = 128 . | Patients with early death, n = 14 . | Patients without early death, n = 114 . | P value∗ . |
|---|---|---|---|---|
| Sex (male:female) | 64:64 | 9:5 | 55:59 | .396 |
| Median gestational age (range), wk | 37 (29-40) | 34 (29-38) | 37 (31-40) | .003 |
| Median birth weight (range), g | 2588 (1438-3714) | 2249 (1438-3044) | 2624 (1598-3714) | .035 |
| Median age at diagnosis (range), d | 0 (0-8) | 0 (0-8) | 0 (0-8) | .854 |
| Congenital heart disease, n (%) | 87 (68) | 5 (36) | 82 (72) | .012 |
| Other congenital abnormally, n (%) | 14 (11) | 2 (14) | 12 (11) | .651 |
| Chromosomal status, n | ||||
| Trisomy 21:mosaic trisomy 21:normal karyotype | 126:1:1 | 14:0:0 | 112:1:1 | 1.000 |
| Median WBC count at diagnosis (range), ×109/L | 48.3 (4.7-478.7) | 157.3 (14.3-238.5) | 44.3 (4.7-478.7) | .006 |
| Median blasts percentage in PB at diagnosis (range), % | 41 (1-96) | 60 (5-95) | 37 (1-96) | .057 |
| Direct bilirubin, median (range), mg/dL | 0.8 (0-12.3) | 1.0 (0.3-5.6) | 0.7 (0-12.3) | .134 |
| Hepatomegaly, median (range)†, cm | 3 (0-8) | 5 (0-8) | 2 (0-7) | .043 |
| Systemic edema, n (%) | 26 (20) | 11 (79) | 15 (13) | <.001 |
| Organ hemorrhage, n (%) | 12 (9) | 4 (29) | 8 (7) | .027 |
| Therapeutic interventions, n (%) | 60 (47) | 11 (79) | 49 (43) | .021 |
| LDAC, n (%) | 46 (36) | 6 (43) | 40 (35) | .586 |
| Exchange blood transfusion, n (%) | 16 (13) | 4 (29) | 12 (11) | .076 |
| Systemic steroid therapy, n (%) | 24 (19) | 8 (57) | 16 (14) | <.001 |
| Classification of GATA1 mutation | ||||
| High-expression type mutation, n (%) | 57 (45) | 6 (43) | 51 (45) | 1.000 |
| Low-expression type mutation, n (%) | 58 (45) | 6 (43) | 52 (46) | 1.000 |
| Unclassified mutation, n (%) | 12 (9) | 2 (14) | 10 (9) | .620 |
| Negative, n (%) | 1 (1) | 0 | 1 (1) | 1.000 |
| Events‡ , n (%) | 42 (33) | 14 (100) | 28 (25) | <.001 |
| Early deaths (age <9 mo), n (%) | 14 (11) | 14 (100) | 0 (0) | <.001 |
| Later phase deaths (after 9 mo), n (%) | 5 (4) | 0 (0) | 5 (4) | 1.000 |
| Leukemia development, n (%) | 23 (18) | 0 (0) | 23 (20) | .073 |
| . | All patients, N = 128 . | Patients with early death, n = 14 . | Patients without early death, n = 114 . | P value∗ . |
|---|---|---|---|---|
| Sex (male:female) | 64:64 | 9:5 | 55:59 | .396 |
| Median gestational age (range), wk | 37 (29-40) | 34 (29-38) | 37 (31-40) | .003 |
| Median birth weight (range), g | 2588 (1438-3714) | 2249 (1438-3044) | 2624 (1598-3714) | .035 |
| Median age at diagnosis (range), d | 0 (0-8) | 0 (0-8) | 0 (0-8) | .854 |
| Congenital heart disease, n (%) | 87 (68) | 5 (36) | 82 (72) | .012 |
| Other congenital abnormally, n (%) | 14 (11) | 2 (14) | 12 (11) | .651 |
| Chromosomal status, n | ||||
| Trisomy 21:mosaic trisomy 21:normal karyotype | 126:1:1 | 14:0:0 | 112:1:1 | 1.000 |
| Median WBC count at diagnosis (range), ×109/L | 48.3 (4.7-478.7) | 157.3 (14.3-238.5) | 44.3 (4.7-478.7) | .006 |
| Median blasts percentage in PB at diagnosis (range), % | 41 (1-96) | 60 (5-95) | 37 (1-96) | .057 |
| Direct bilirubin, median (range), mg/dL | 0.8 (0-12.3) | 1.0 (0.3-5.6) | 0.7 (0-12.3) | .134 |
| Hepatomegaly, median (range)†, cm | 3 (0-8) | 5 (0-8) | 2 (0-7) | .043 |
| Systemic edema, n (%) | 26 (20) | 11 (79) | 15 (13) | <.001 |
| Organ hemorrhage, n (%) | 12 (9) | 4 (29) | 8 (7) | .027 |
| Therapeutic interventions, n (%) | 60 (47) | 11 (79) | 49 (43) | .021 |
| LDAC, n (%) | 46 (36) | 6 (43) | 40 (35) | .586 |
| Exchange blood transfusion, n (%) | 16 (13) | 4 (29) | 12 (11) | .076 |
| Systemic steroid therapy, n (%) | 24 (19) | 8 (57) | 16 (14) | <.001 |
| Classification of GATA1 mutation | ||||
| High-expression type mutation, n (%) | 57 (45) | 6 (43) | 51 (45) | 1.000 |
| Low-expression type mutation, n (%) | 58 (45) | 6 (43) | 52 (46) | 1.000 |
| Unclassified mutation, n (%) | 12 (9) | 2 (14) | 10 (9) | .620 |
| Negative, n (%) | 1 (1) | 0 | 1 (1) | 1.000 |
| Events‡ , n (%) | 42 (33) | 14 (100) | 28 (25) | <.001 |
| Early deaths (age <9 mo), n (%) | 14 (11) | 14 (100) | 0 (0) | <.001 |
| Later phase deaths (after 9 mo), n (%) | 5 (4) | 0 (0) | 5 (4) | 1.000 |
| Leukemia development, n (%) | 23 (18) | 0 (0) | 23 (20) | .073 |